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Acute lymphoblastic leukaemia (ALL) is the most common childhood cancer. This disease has 80-90% of cure rate. 
Thiopurines are one of the most used types of drugs in ALL therapy. The 6-MP is metabolized into 6-thioguanine 
nucleotides (6-TGNs) and into 6-methyl mercaptopurine nucleotides (6-MMPNs). Its antineoplastic property arises 
from the incorporation of 6-TGNs into DNA or RNA resulting in cell cycle arrest and apoptosis and the inhibition of 
de novo purine synthesis due to 6-MMPNs.  
 
 
The case of thiopurines for ALL therapy is a good example of pharmacogenetics. The aim of this science is to 
develop personalize treatments studying polymorphisms of genes involved in pharmacokinetics (drug metabolism) 
and pharmacodynamics (drug efficacy or toxicity).  
The balance between 6-TGNs and 6-MMPNs explains the major part of the toxicities of this treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
   
 
 
 
 
 
 
  
 
 
Thiopurine S-methyltransferase (TPMT)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
Cost-effectiveness of genotyping TPMT gene 
ALL patients treated with standard doses 
of thiopurines and with one or two non-
functional allelic variants of TPMT 
Greater risk of dose-dependent 
myelotoxycity and a bigger likelihood of 
suffering secondary cancers1  
Figure 1: metabolism of thiopurines. Produgs  are 6-mercaptopurine 
(6-MP), thioguanine (TG) and azathioprine (AZA).  
When  ALL patients are homozygous wild-type for TPMT or when  
doses are adjusted for TPMT genotype,  other genes have a 
significant influence on thiopurines-induced toxicity 
Inosine triphosphate pyrophosphate (ITPA) 
Introduction 
Other genes releated with pharmacogenetics of ALL 
Figure 2: TPMT wild-type and three allelic variants implicated in 
the reduced activity of the TPMT protein 
Genotyping tests and individualization 
adjustments in the dosage decease 
thiopurine adverse effects without 
compromising the efficacy 
TPMT activity is also related with … 
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This is a cytosolic enzyme that catalyses the hydrolysis of 6-thioinosine 
triphosphate (6-TITP) to 6-thioinosine monophosphate (6-TIMP). When ITPA 
activity is reduced, there is an accumulation of 6-TITP (metabolized into 6-
MMPNs by TPMT). Too much 6-MMPNs causes febrile neutropenia4. 
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Figure 5: cumulative incidence of GI toxicity and the corresponding genotypes of 
TPMT, PACSIN2 and SLCO1B15 modified 
Analysis done by the Institute for Prospective Technological Studies (IPTS) 
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Cost-
effectiveness 
was defined as 
a cost per life-
year gained 
Genotyping for TPMT 
gene in ALL patients 
prior to thiopurines 
treatment was highly 
cost-effectiveness 
2100€ per 
life-year 
gained6 
 
 Some SNPs from TPMT gene cause a decrease of enzyme activity  toxic 6-TGNs accumulation  
 At any hospital in Spain, TPMT genotypage is performed in ALL patients. In other hospitals like St. 
Jude Children’s Research Hospital, ALL patients are genotyped for TPMT  
 There are other genes related with the individual response to thiopurines  ITPA, MTHFR, MRP4, 
SLCO1B1  and PACSIN2  
 Polymorphisms on all these genes influence also other variables  event-free survival, relapse rates 
or secondary cancers 
 More hospitals have to consider seriously genotyping TPMT as an essential part of therapy of ALL 
patients  genotyping costs are expected to decline in the future 
We have the knowledge and the technology, so we should enforce it to the clinic to improve lives. 
Conclusions and future purposes 
Goals of the bibliographic research project  
How do polymorphisms 
in TPMT gene influence 
individual response to 
thiopurines? 
How is the situation of 
genotyping  TPMT gene 
around the world? And 
in Spain? 
Are there other genes 
implicated in the 
pharmacogenetics of 
thiopurines?  
Which are the other 
consequencies of the 
polimorphisms of these 
genes? 
Methylenetetrahydrofolate reductase (MTHFR) 
The deficiency of this enzyme is related with 
homocysteinuria  
Multi-drug resistance protein 4 (MRP4) 
The deficiency of this nucleotide transporter 
increase the risk of a 6-TGNs accumulation 
Multilocus genotype TPMT –  SLCO1B1 – PACSIN2 
SNPs on these three genes found by a genome wide 
analysis are related with gastrointestinal toxicity5  
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At any given thiopurines dose intensity, intermediate and 
low TMPT activity better event-free survival (EFS)2 
The incidence of relapse  not higher among TMPT 
heterozygous than wild-type homozygous3 
Homozygous wild-type TPMT  higher concentrations of 
6-MMPNs   hepatotoxicity 
Figure 3: Kaplan-Meier curves for EFS according 
to TPMT status2modified 
Figure 4: Cumulative incidence of relapse comparing 
TPMT heterozygotes and wild-type3modified 
Thiopurine S-methyltransferase (TPMT) is a cytosolic  
enzyme that catalyses S-methylation of thiopurines. 
When TPMT activity is reduced or deficient , there is  
an accumulation of 6-TGNs because the S-
methylation pathway is hardly inactivated.  
At Spain, any 
hospital 
perform TPMT 
genotypage in 
ALL patients 
At some 
hospitals 
around the 
word, ALL 
patients are 
genotyped for 
TPMT  
Clinical 
Pharmacogenetics 
Implementation 
Consortium (CPIC) 
dosage guidelines 
